Relmada Therapeutics (RLMD) Income from Continuing Operations (2012 - 2026)
Relmada Therapeutics (RLMD) reported Income from Continuing Operations of 18501992.0 for Q1 2026, down 4.07% year-over-year from 19287280.92 in Q1 2025, and up 7.24% on a QoQ basis from 19945881.0 in Q4 2025.
Relmada Therapeutics (RLMD) has 15 years of Income from Continuing Operations data on file, last reported at 18501992.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 4.07% year-over-year to 18501992.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 58428054.0 (up 23.33% YoY) and the FY2025 annual result came in at 57704211.0, up 28.19% from the prior year.
- Income from Continuing Operations rose to 18501992.0 in Q1 2026 per RLMD's latest filing, from 19945881.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 9899848.0 in Q2 2025 and bottomed at 45512072.0 in Q2 2022.
- The 5-year median for Income from Continuing Operations is 21931972.0 (2024), against an average of 24492169.53.
- The widest annual swing landed in 2022, when Income from Continuing Operations tumbled 71.99%; it then soared 54.5% in 2025.
- Tracing RLMD's Income from Continuing Operations over 5 years: stood at 38702420.0 in 2022, then jumped by 33.93% to 25570094.0 in 2023, then increased by 27.96% to 18420912.0 in 2024, then retreated by 8.28% to 19945881.0 in 2025, then rose by 7.24% to 18501992.0 in 2026.
- Per Business Quant, the three latest RLMD Income from Continuing Operations figures stand at 18501992.0 (Q1 2026), 19945881.0 (Q4 2025), and 10080333.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - | -18.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.50 Mn |
| Dec 31, 2025 | -19.95 Mn |
| Sep 30, 2025 | -10.08 Mn |
| Jun 30, 2025 | -9.90 Mn |
| Mar 31, 2025 | -17.78 Mn |
| Dec 31, 2024 | -18.42 Mn |
| Sep 30, 2024 | -22.15 Mn |
| Jun 30, 2024 | -17.86 Mn |
| Mar 31, 2024 | -21.93 Mn |
| Dec 31, 2023 | -25.57 Mn |
| Sep 30, 2023 | -21.37 Mn |
| Jun 30, 2023 | -24.66 Mn |
| Mar 31, 2023 | -26.95 Mn |
| Dec 31, 2022 | -38.70 Mn |
| Sep 30, 2022 | -38.74 Mn |
| Jun 30, 2022 | -45.51 Mn |
| Mar 31, 2022 | -38.30 Mn |
| Dec 31, 2021 | -34.18 Mn |
| Sep 30, 2021 | -42.65 Mn |
| Jun 30, 2021 | -26.46 Mn |
| Mar 31, 2021 | -22.41 Mn |
| Dec 31, 2020 | -20.92 Mn |
| Sep 30, 2020 | -16.82 Mn |
| Jun 30, 2020 | -12.35 Mn |
| Mar 31, 2020 | -9.97 Mn |
| Dec 31, 2019 | -8.27 Mn |
| Sep 30, 2019 | -3.67 Mn |
| Jun 30, 2019 | -4.12 Mn |
| Mar 31, 2019 | -2.70 Mn |
| Dec 31, 2018 | -3.48 Mn |
| Sep 30, 2018 | -2.41 Mn |
| Mar 31, 2018 | -2.95 Mn |
| Dec 31, 2017 | -1.77 Mn |
| Sep 30, 2017 | -978,334.00 |
| Jun 30, 2017 | -1.78 Mn |
| Mar 31, 2017 | -2.28 Mn |
| Dec 31, 2016 | -1.54 Mn |
| Sep 30, 2016 | -1.62 Mn |
| Jun 30, 2016 | -3.10 Mn |
| Mar 31, 2016 | -2.75 Mn |
| Dec 31, 2015 | -5.72 Mn |
| Sep 30, 2015 | -4.63 Mn |
| Jun 30, 2015 | -4.40 Mn |
| Mar 31, 2015 | -4.58 Mn |
| Dec 31, 2014 | -4.38 Mn |
| Sep 30, 2014 | -3.72 Mn |
| Jun 30, 2014 | -13.38 Mn |
| Mar 31, 2014 | -835,696.00 |
| Nov 30, 2013 | -14,374.00 |
| May 31, 2013 | -19,485.00 |
| Feb 28, 2013 | -4,146.00 |
| Nov 30, 2012 | -9,020.00 |
| Aug 31, 2012 | -8,629.00 |
| May 31, 2012 | -2,481.00 |